1-20 of 23
radiation therapy, adaptive
Close
Sort by
Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Clinical Trials & Observations
Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster, Peter H. Sayre, Matthew J. Wieduwilt, Anjali S. Advani, John E. Godwin, Martha L. Arellano, Kendra L. Sweet, Ashkan Emadi, Farhad Ravandi, Harry P. Erba, Michael Byrne, Laura Michaelis, Max S. Topp, Norbert Vey, Fabio Ciceri, Matteo Giovanni Carrabba, Stefania Paolini, Gerwin A. Huls, Mojca Jongen-Lavrencic, Martin Wermke, Patrice Chevallier, Emmanuel Gyan, Christian Récher, Patrick J. Stiff, Kristen M. Pettit, Bob Löwenberg, Sarah E. Church, Erica Anderson, Jayakumar Vadakekolathu, Marianne Santaguida, Michael P. Rettig, John Muth, Teia Curtis, Erin Fehr, Kuo Guo, Jian Zhao, Ouiam Bakkacha, Kenneth Jacobs, Kathy Tran, Patrick Kaminker, Maya Kostova, Ezio Bonvini, Roland B. Walter, Jan K. Davidson-Moncada, Sergio Rutella, John F. DiPersio
Journal: Blood
Blood (2021) 137 (6): 751–762.
https://doi.org/10.1182/blood.2020007732
Published: 2021
Includes: Supplemental data
Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, Peter H. Sayre, MD PhD, Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD PhD, Norbert Vey, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD PhD, Sarah E. Church, PhD, Michael P. Rettig, PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD PhD, Gerwin Huls, MD PhD, Farhad Ravandi, MD, John Muth, MS, Kathy Tran, Mojca Jongen-Lavrencic, MD PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jayakumar Vadakekolathu, PhD, Jon M. Wigginton, MD, Ezio Bonvini, MD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MD PhD MS, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 733.
https://doi.org/10.1182/blood-2019-122073
Published: 2019
Journal Articles

A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART ® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Pau Montesinos, MD PhD, Maria Calbacho, MD, Jordi Sierra Gil, MD PhD, Jaime Perez De Oteyza, MD PhD, Jacob M. Rowe, MB, BS, Ofir Wolach, MD, Yishai Ofran, MD, Yakir Moshe, MD, Jichao Sun, PhD, Jan Baughman, MPH, Eileen McNulty, MS, Ezio Bonvini, MD, Jon M. Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2662.
https://doi.org/10.1182/blood-2019-125966
Published: 2019
Journal Articles

Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

Ouiam Bakkacha, MD, Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, Peter H. Sayre, MD PhD, Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD PhD, Norbert Vey, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD PhD, Gerwin Huls, MD PhD, Farhad Ravandi, MD, Kathy Tran, John Muth, MS, Jan Baughman, MPH, Mojca Jongen-Lavrencic, MD PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jon Wigginton, MD, Ezio Bonvini, MD, Roland B. Walter, MD PhD MS, Jan Davidson, John F. DiPersio, MD PhD, Kenneth Jacobs, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5144.
https://doi.org/10.1182/blood-2019-127138
Published: 2019
Journal Articles

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Anne W. J. Martens, MSc, Susanne R. Janssen, MSc, Ingrid A.M. Derks, Sanne Tonino, MD PhD, Eric Eldering, Gerritje J. W. van der Windt, Arnon P. Kater, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3043.
https://doi.org/10.1182/blood-2019-123350
Published: 2019
Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1410.
https://doi.org/10.1182/blood-2019-128485
Published: 2019
Journal Articles

A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients

Maria Ortiz, Fadi Towfic, PhD, Mehmet Kemal Samur, PhD, Erin Flynt, In Sock Jang, PhD, Kai Wang, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Matthew Trotter, PhD, Gareth Morgan, MD, Nikhil Munshi, MD, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3165.
https://doi.org/10.1182/blood-2018-99-117114
Published: 2018
Journal Articles

Bone Marrow T Cell Changes By Multiplex IHC after Treatment with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Protein, in a Primary Refractory t-AML Patient

John Godwin, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4065.
https://doi.org/10.1182/blood-2018-99-118522
Published: 2018
Journal Articles

FANCI-FANCD2 Binds RNA, Which Stimulates Its Monoubiquitination

Zhuobin Liang, PhD, Yaqun Teng, PhD, Jingchun Liu, MD, Simonne Longerich, PhD, Xiaoyong Chen, Allison M. Green, PhD, Natalie Collins, MD PhD, Li Lan, MD PhD, Patrick Sung, PhD, Gary M. Kupfer, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 645.
https://doi.org/10.1182/blood-2018-99-118863
Published: 2018
Journal Articles

Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart ® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Sergio Rutella, MD PhD FRCPath, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Elena Viboch, MSc, Amy H Sullivan, BSc, Tressa Hood, MSc, Sarah E. Warren, PhD, Alessandra Cesano, MD PhD, Ross La Motte-Mohs, PhD, John Muth, MS, Helene Lelièvre, PhD PharmD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 444.
https://doi.org/10.1182/blood-2018-99-111539
Published: 2018
Journal Articles

A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART ® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules

Ezio Bonvini, MD, Ross La Motte-Mohs, PhD, Ling Huang, Chia-Ying Kao Lam, PhD, Thomas Kaufman, Liqin Liu, PhD, Ralph F. Alderson, PhD, Kurt Stahl, Jennifer G. Brown, PhD, Hua Li, Sharad Sharma, PhD, James Tamura, PhD, Syd Johnson, PhD, Paul Moore, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5230.
https://doi.org/10.1182/blood-2018-99-116264
Published: 2018
Journal Articles

Management of Cytokine Release Syndrome in AML Patients Treated with Flotetuzumab, a CD123 x CD3 Bispecific Dart ® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, Cedric Viero, PhD, John Godwin, MD, Jan Baughman, MPH, Jichao Sun, PhD, Kang Ying, John Muth, MS, Shengyan Hong, PhD, Norbert Vey, MD PhD, Kendra L. Sweet, MD, Geoffrey L. Uy, MD, Farhad Ravandi, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P. Rettig, PhD, Max S. Topp, Gerwin Huls, MD PhD, Helene Lelièvre, PhD PharmD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Bob Lowenberg, MD, John F. DiPersio, MD PhD, Jon Wigginton, MD, Jan K Davidson-Moncada, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2738.
https://doi.org/10.1182/blood-2018-99-112615
Published: 2018
Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

Farhad Ravandi, MD, Asad Bashey, MD PhD, James M. Foran, MD, Wendy Stock, MD, Raya Mawad, MD, William Blum, MD, M. Wayne Saville, MD, Chelsea M. Johnson, BSN, K. Gary J. Vanasse, MD, Thomas Ly, PhD, Hagop M. Kantarjian, MD, Bhavana Bhatnagar, DO, Koichi Takahashi, MD, Alice S. Mims, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 763.
https://doi.org/10.1182/blood-2018-99-119786
Published: 2018
Journal Articles

Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart ® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Geoffrey L. Uy, MD, Michael P. Rettig, PhD, Norbert Vey, MD PhD, John Godwin, MD, Matthew C Foster, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Max S. Topp, Gerwin Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Kendra L. Sweet, MD, Farhad Ravandi, MD, Sarah E. Church, PhD, Jayakumar Vadakekolathu, PhD, Sergio Rutella, MD PhD FRCPath, Jichao Sun, PhD, Kang Yang, Jan Baughman, MPH, Teia Curtis, PhD, Erin Timmeny, Kerri Cali, Kathy Tran, John Muth, MS, Ross La Motte-Mohs, PhD, Camille Poirot, Pharm.D., Athanasios Pallis, MD, Alessandra Cesano, MD PhD, Ezio Bonvini, MD, Jon Wigginton, MD, Bob Lowenberg, MD, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 764.
https://doi.org/10.1182/blood-2018-99-117085
Published: 2018
Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1365.
https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365
Published: 2017
Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Geoffrey L. Uy, MD, John Godwin, MD, Michael P Rettig, PhD, Norbert Vey, Matthew Foster, Martha L. Arellano, MD, David A. Rizzieri, MD, Max S. Topp, MD, Gerwin Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Helene Lelièvre, PhD PharmD, Ross La Motte-Mohs, PhD, Daner Li, MS, Jichao Sun, PhD, Kenneth Jacobs, MD, Karen Spohn, BS, Nadia Lonsdale, BA, Kathy Tran, Jan Baughman, MPH, Michele Shannon, PhD, Bernard Fox, PhD, Ezio Bonvini, MD, Jon Wigginton, Jan Davidson-Moncada, MD, John F DiPersio, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 637.
https://doi.org/10.1182/blood.V130.Suppl_1.637.637
Published: 2017
Journal Articles

Lead-in Dose Optimization to Mitigate Cytokine Release Syndrome in AML and MDS Patients Treated with Flotetuzumab, a CD123 x CD3 Dart® Molecule for T-Cell Redirected Therapy

Kenneth Jacobs, MD, John Godwin, MD, Matthew Foster, Norbert Vey, Geoffrey L. Uy, MD, David A. Rizzieri, MD, Martha L. Arellano, MD, Michael P Rettig, PhD, Stephanie Christ, MS, Max S. Topp, MD, Geert Huls, MD PhD, Bob Lowenberg, MD PhD, Giovanni Martinelli, MD, Stefania Paolini, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Jichao Sun, PhD, Daner Li, MS, Kathy Tran, Karen Spohn, BS, Jan Baughman, MPH, Sadhna Shankar, MDMPH, Helene Lelièvre, PhD PharmD, Ezio Bonvini, MD, John F DiPersio, MD PhD, Jon Wigginton, Jan K davidson-Moncada, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3856.
https://doi.org/10.1182/blood.V130.Suppl_1.3856.3856
Published: 2017
Journal Articles

Targeting CD123 in acute myeloid leukemia using a T-cell–directed dual-affinity retargeting platform

Muneera Al-Hussaini, Michael P. Rettig, Julie K. Ritchey, Darja Karpova, Geoffrey L. Uy, Linda G. Eissenberg, Feng Gao, William C. Eades, Ezio Bonvini, Gurunadh R. Chichili, Paul A. Moore, Syd Johnson, Lynne Collins, John F. DiPersio
Journal: Blood
Blood (2016) 127 (1): 122–131.
https://doi.org/10.1182/blood-2014-05-575704
Published: 2016
Includes: Supplemental data
Journal Articles

Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs ® )

Muneera H. AL Hussaini, MBBS, Julie Ritchey, Michael P. Rettig, PhD, Linda Eissenberg, PhD, Geoffrey L. Uy, MD, Gurunadh Chichili, PhD, Paul A Moore, PhD, Syd Johnson, PhD, Lynne Collins, Ezio Bonvini, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 360.
https://doi.org/10.1182/blood.V122.21.360.360
Published: 2013
Journal Articles

A New Platform For Trivalent Bispecific Antibodies Used For T-Cell Redirected Killing Of B-Cell Malignancies

Diane L Rossi, M.S., Edmund A Rossi, Ph.D, David M Goldenberg, ScD, MD, Chien-Hsing Chang, Ph.D
Journal: Blood
Blood (2013) 122 (21): 3078.
https://doi.org/10.1182/blood.V122.21.3078.3078
Published: 2013